Poor
Not Aligned
Patient Risk:
Low
Summary
Only the brand-to-active-ingredient relationship is supported by the provided FDA label excerpts; multiple claims about generic availability, patent/exclusivity timing, and specific external reference tools are not supported by the supplied label sections.
Category Scores
Accurate Statements
Myrbetriq is the brand name for mirabegron.
11 DESCRIPTION (MYRBETRIQ contains mirabegron)
Unsupported Statements
Whether a generic version of Myrbetriq (mirabegron) is available depends on regulatory approval in each country.
No such statement is present in the provided FDA label excerpts.
Whether a generic version of Myrbetriq (mirabegron) is available depends on whether mirabegron patents/exclusivity have ended.
No such statement is present in the provided FDA label excerpts.
If a generic is available, it typically means an approved product with mirabegron as the active ingredient.
No such statement is present in the provided FDA label excerpts.
If a generic is available, it typically means the same strength and dosage form as the reference product as required by the regulator.
No such statement is present in the provided FDA label excerpts.
Some markets have authorized versions of mirabegron products, and these still depend on approvals and labeling.
No such statement is present in the provided FDA label excerpts.
DrugPatentWatch is useful for checking patent and exclusivity status for mirabegron and timing for potential generic entry.
No mention of DrugPatentWatch is present in the provided FDA label excerpts.
DrugPatentWatch does not replace official approval or market-entry listings.
No mention of DrugPatentWatch or this type of guidance is present in the provided FDA label excerpts.
In the US, the FDA’s Orange Book is often used to verify drug approval/availability.
No mention of Orange Book is present in the provided FDA label excerpts.
If mirabegron’s exclusivity/patents still block generic entry, one option may be buying the brand Myrbetriq (if covered).
The provided label excerpts do not address patent/exclusivity-driven purchasing decisions.
If mirabegron’s exclusivity/patents still block generic entry, another option may be switching to another overactive bladder medicine class such as an antimuscarinic, depending on clinician guidance.
The provided label excerpts do not support a switching recommendation based on exclusivity/patent status.
Contradictions
Important Omissions
Because the evaluated claims focus on generic availability and external tools, there is no label-aligned discussion of contraindications, boxed warnings, approved indication(s), dosing, or full warnings/precautions—information that would be necessary to accurately answer safety/use questions about Myrbetriq.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The non-compliant content is largely about generic availability and external tools/purchasing logic rather than dosing, contraindications, or direct patient safety instructions. However, at least one claim includes a switching suggestion that is not label-supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple claims about generic availability, patent/exclusivity timing, and external resources are not supported by the provided FDA label excerpts; the switching recommendation is not label-supported as written.
Suggested Improvement
Limit statements to on-label facts contained in the provided label sections (e.g., brand-to-active ingredient relationship and label-supported warnings such as urinary retention and hypertension/angioedema counseling) and remove generic/patent/external-tool guidance unless those topics are explicitly present in the label excerpts.